TuftsCSDD-Logo-Color.jpg
Drug Companies Still Under Pressure to Increase Pace of Development, According to Tufts Center for the Study of Drug Development
06 janv. 2010 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 6, 2010) - Although drug developers are improving R&D efficiency, in part by terminating more unpromising drugs earlier in development, their continued success...
TuftsCSDD-Logo-Color.jpg
New Products to Treat Neglected Diseases Are on the Rise, According to Tufts Center for the Study of Drug Development
17 nov. 2009 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 17, 2009) - New products to treat neglected diseases have received marketing approval from regulatory agencies at a steadily increasing rate in recent years as...
TuftsCSDD-Logo-Color.jpg
Top Performing Drug Developers Are Merging Operational and Strategic Objectives, According to Tufts Center for the Study of Drug Development
30 oct. 2009 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - October 30, 2009) - Drug companies racing to develop new products to replace drugs coming off patent are finding that success is increasingly tied to the company's ability...
TuftsCSDD-Logo-Color.jpg
Marketing Exclusivity for First-in-Class Drugs Has Shortened to 2.5 Years, According to Tufts Center for the Study of Drug Development
09 sept. 2009 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 9, 2009) - Marketing exclusivity periods for first-in-class drugs have fallen dramatically in recent decades -- from a median of 10.2 years in the 1970s to 2.5...
TuftsCSDD-Logo-Color.jpg
Large Pharmaceutical Firms Are Getting More Drugs Into Development While Terminating Unpromising Candidates, According to Tufts Center for the Study of Drug Development
22 juil. 2009 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 22, 2009) - Large pharmaceutical firms, under pressure to bring new medicines to market faster, have been getting more drug candidates into development in recent years...
TuftsCSDD-Logo-Color.jpg
New Drug R&D Increasingly Depends on Partnerships Between Drug Sponsors and Service Providers, According to Tufts Center for the Study of Drug Development
08 juil. 2009 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 8, 2009) - If drug developers are to remain competitive, they must rely less on traditional outsourcing, in which external service providers offer a way to quickly...
TuftsCSDD-Logo-Color.jpg
Number of Therapeutic Peptides in Clinical Study Has Nearly Doubled Since the 1990s, According to Tufts Center for the Study of Drug Development
20 mai 2009 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - May 20, 2009) - Since 2000, the number of therapeutic peptides in clinical study has nearly doubled the 1990s rate, due in part to advances in synthesis, delivery, and...
NineSigma Report Benchmarks State of Open Innovation
29 avr. 2009 16h46 HE | NineSigma, Inc.
CLEVELAND, OH--(Marketwire - April 29, 2009) - NineSigma, the leading provider of open innovation solutions, today released the results of its first open innovation (OI) study that establishes a...
TuftsCSDD-Logo-Color.jpg
Pharmaceutical Licensing Success Is Tied to Clarity of Strategy on Both Sides, According to Tufts Center for the Study of Drug Development
16 avr. 2009 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - April 16, 2009) - Pharmaceutical firms looking to license new drug candidates from other firms will improve their chances of achieving a successful alliance if they focus on...
NineSigma and KnowledgeWorks Partnership Expands Open Innovation in South Korea
31 mars 2009 10h48 HE | NineSigma, Inc.
CLEVELAND, OH--(Marketwire - March 31, 2009) - NineSigma, the leading provider of open innovation solutions, today announced a strategic partnership between its Asian company, NineSigma Japan, Inc.,...